백신 시장 예측(-2030년) : 백신 유형별, 질환 유형별, 투여 경로별, 연령층별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Vaccines Market is accounted for $80.24 billion in 2024 and is expected to reach $97.38 billion by 2030 growing at a CAGR of 6.2% during the forecast period. Vaccines are biological preparations designed to provide immunity against specific diseases. They contain weakened or inactive parts of a pathogen, such as proteins or genetic material, which stimulate the immune system to recognize and fight the pathogen. By triggering an immune response, vaccines help the body develop memory cells that can recognize and combat the pathogen if exposed in the future. This proactive approach helps prevent infections and their potential complications, contributing to individual and public health.

According to the United Nations Health Agency, as of September 2021, only 3% of people had been vaccinated with at least one dose of the covid -19 vaccine, compared to 60.18% in high-income countries.

Market Dynamics:

Driver:

Rising incidence of infectious diseases

As new and re-emerging diseases spread, both governments and healthcare organizations prioritize vaccination to protect public health and mitigate outbreaks. This heightened need drives investments in vaccine research, development, and production. Additionally, increased disease prevalence raises public awareness and urgency, encouraging higher vaccination rates and expanding market opportunities. Consequently, pharmaceutical companies and research institutions are motivated to innovate and scale up vaccine solutions, further fueling market growth.

Restraint:

Adverse reactions and safety concerns

Adverse reactions and safety concerns in vaccines arise from individual responses, potential side effects, or rare complications. These issues can stem from vaccine components, manufacturing processes, or underlying health conditions. Such concerns may lead to public skepticism and decreased vaccine uptake. Negative reports and misinformation can further amplify fears, impacting overall vaccination rates. This reduced trust and lower demand can hamper market growth.

Opportunity:

Mounting government initiatives and funding

Governments allocate substantial resources to support vaccine R&D, facilitating the creation of innovative vaccines and faster response to emerging diseases. Public funding also helps reduce the cost of vaccine production and makes vaccines more accessible, particularly in underserved regions. Additionally, government-led immunization programs increase vaccination rates, boost public health, and drive market demand. These efforts collectively strengthen the vaccine supply chain and promote global health security, fostering overall market growth.

Threat:

High development and production costs

High development and production costs in vaccines arise from extensive research, clinical trials, and stringent regulatory requirements. Manufacturing involves complex processes, quality control, and specialized equipment, further increasing expenses. Consequently, high costs can slow market growth by restricting vaccine availability, impeding widespread immunization efforts, and limiting investments in new vaccine development and innovation.

Covid-19 Impact

The covid-19 pandemic significantly propelled the vaccines market by accelerating vaccine development and production, highlighting the critical role of rapid response in public health. The crisis led to unprecedented global collaboration and funding, resulting in the swift creation and distribution of covid-19 vaccines. This experience boosted interest and investment in vaccine research and infrastructure. However, it also exposed challenges such as vaccine distribution inequities and public hesitancy. Overall, the pandemic underscored the importance of vaccines and spurred advancements in the industry, influencing future market dynamics.

The pediatric segment is expected to be the largest during the forecast period

The pediatric segment is estimated to have a lucrative growth. Pediatric vaccines are immunizations specifically designed for children to protect against common and serious diseases. These vaccines are crucial for preventing illnesses such as measles, mumps, rubella, and whooping cough. Early vaccination helps establish immunity before children are exposed to these pathogens. Immunization schedules are carefully designed to ensure timely protection, contributing to overall public health and reducing disease outbreaks.

The research institutions segment is expected to have the highest CAGR during the forecast period

The research institutions segment is anticipated to witness the highest CAGR growth during the forecast period. In research institutions, vaccines are used to advance scientific understanding and develop new immunization technologies. These institutions conduct studies on vaccine efficacy, safety, and innovative delivery methods. They explore novel vaccine platforms, and investigate new targets for disease prevention. Research-driven vaccine development aims to address emerging and existing diseases, improving public health outcomes and advancing medical science.

Region with largest share:

The vaccines market in the Asia-Pacific region is experiencing rapid growth due to increasing healthcare investments, rising disease incidence, and expanding immunization programs. Governments are prioritizing vaccine accessibility and affordability, driven by high population density and emerging disease threats. Innovations in vaccine technology and robust public health initiatives further stimulate market expansion. The region remains a key area for vaccine development and distribution, reflecting its growing healthcare needs.

Region with highest CAGR:

The vaccines market in North America is robust, driven by advanced healthcare infrastructure, high vaccination rates, and significant investments in research and development. The region benefits from strong government support, including funding and public health initiatives, as well as a high level of public awareness about vaccine benefits. The market is also fuelled by ongoing innovation and the rapid development of new vaccines. Overall, North America remains a leading player in the global vaccine market.

Key players in the market

Some of the key players profiled in the Vaccines Market include Pfizer Inc., Moderna Inc., Johnson & Johnson, Sanofi Pasteur, GlaxoSmithKline (GSK), AstraZeneca, Novartis AG, Merck & Co., Inc., Bavarian Nordic, BioNTech SE, Serum Institute of India, CureVac N.V., Abbott Laboratories, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Indian Immunologicals Limited (IIL), Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company and Sinovac Biotech.

Key Developments:

In January 2024, Indian Immunologicals Ltd (IIL), a wholly-owned subsidiary of National Dairy Development Board (NDDB), launched India's 'first' indigenously developed Hepatitis A vaccine. Havisure is expected to play a key role to protect against the Hepatitis A virus, which primarily affects the liver. The vaccine is effective in preventing the disease and is recommended for children in routine immunisation.

In November 2022, Pfizer Inc. and BioNTech SE have advanced a promising vaccine candidate into clinical trials. Their new mRNA-based combination vaccine aims to tackle two significant respiratory illnesses: influenza and COVID-19. This vaccine, currently in Phase 1 trials, represents a notable step forward in public health innovation.

Vaccine Types Covered:

• Inactivated Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• mRNA (messenger Ribonucleic Acid) Vaccines
• DNA (Deoxyribonucleic Acid) Vaccines
• Toxoid Vaccines
• Other Vaccine Types

Disease Types Covered:

• Infectious Diseases
• Cancer Vaccines
• Autoimmune Diseases
• Travel-Related Vaccines
• Other Disease Types

Route of Administrations Covered:

• Injectable
• Oral
• Nasal
• Transdermal

Age Groups Covered:

• Pediatric
• Adult
• Geriatric

End Users Covered:

• Hospitals
• Pharmacies
• Public Health Organizations
• Research Institutions
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Vaccines Market, By Vaccine Type

• 5.1 Introduction
• 5.2 Inactivated Vaccines
• 5.3 Live Attenuated Vaccines
• 5.4 Conjugate Vaccines
• 5.5 mRNA (messenger Ribonucleic Acid) Vaccines
• 5.6 DNA (Deoxyribonucleic Acid) Vaccines
• 5.7 Toxoid Vaccines
• 5.8 Other Vaccine Types

6 Global Vaccines Market, By Disease Type

• 6.1 Introduction
• 6.2 Infectious Diseases
• 6.3 Cancer Vaccines
• 6.4 Autoimmune Diseases
• 6.5 Travel-Related Vaccines
• 6.6 Other Disease Types

7 Global Vaccines Market, By Route of Administration

• 7.1 Introduction
• 7.2 Injectable
• 7.3 Oral
• 7.4 Nasal
• 7.5 Transdermal

8 Global Vaccines Market, By Age Group

• 8.1 Introduction
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

9 Global Vaccines Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Pharmacies
• 9.4 Public Health Organizations
• 9.5 Research Institutions
• 9.6 Other End Users

10 Global Vaccines Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Pfizer Inc.
• 12.2 Moderna Inc.
• 12.3 Johnson & Johnson
• 12.4 Sanofi Pasteur
• 12.5 GlaxoSmithKline (GSK)
• 12.6 AstraZeneca
• 12.7 Novartis AG
• 12.8 Merck & Co., Inc.
• 12.9 Bavarian Nordic
• 12.10 BioNTech SE
• 12.11 Serum Institute of India
• 12.12 CureVac N.V.
• 12.13 Abbott Laboratories
• 12.14 Clover Biopharmaceuticals
• 12.15 Inovio Pharmaceuticals
• 12.16 Indian Immunologicals Limited (IIL)
• 12.17 Bayer AG
• 12.18 Takeda Pharmaceutical Company Limited
• 12.19 Eli Lilly and Company
• 12.20 Sinovac Biotech